Healthcare
Fortress Biotech, Inc.(FBIOP)
Live Price
Offline$20.06
-2.24% today
1Y Change
+157.18%
Window
Jun 26, 2025 โ Jun 18, 2026
- Market Cap
- $80.00M
- Revenue Growth
- +9.7%
- EPS Growth
- +97.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fortress Biotech, Inc. (FBIOP) is a Healthcare stock with a market cap of $80.00M and listed on NASDAQ. The stock last traded around $20.06 and up 157.2% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +9.7%, EPS growth of +97.5%, a dividend yield of 0.0%. What stands out right now is revenue +9.7%, EPS +97.5%, free cash flow +30.9% with operating margin -111.0% and ROIC -50.0%. Valuation is more restrained than many high-expectation growth names at P/E 10.4 and price/sales 1.3. Stock Foundry combines FBIOP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+9.7% vs +7.6% peer median
Operating Margin
Below sector median
-111.0% vs +19.4% peer median
P/E
Below sector median
10.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +9.7% and EPS at +97.5%, with operating margin around -111.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +1.9% | +20.6% | +50.7% |
2026 Mar 31, 2026 | -236.4% | -2.6% | -0.1% | +3.7% |
2025 May 13, 2025 | +2.9% | +2.4% | +1.2% | -9.0% |
Benchmark Edge
FBIOP vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FBIOP
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FBIOP Max Drawdown
-30.61%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FBIOP and SPY.
Company Overview
Fortress Biotech, Inc.
NASDAQ Capital Market
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
- Leadership
- Lindsay Allan Rosenwald
- IPO Date
- Nov 14, 2017
- Employees
- 101
- Street Address
- 1111 Kane Concourse
- Mailing
- Bay Harbor Islands, FL, 33154
- Region
- Bay Harbor Islands, FL, US
- Reporting Currency
- USD
- Investor Line
- 781 652 4500
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 10.4
- EV/EBITDA
- โ
- Price/Sales
- 1.3
- Price/Book
- 1.4
Growth
- Revenue
- +9.7%
- EPS
- +97.5%
- Free Cash Flow
- +30.9%
Profitability
- Gross Margin
- 66.9%
- Operating Margin
- -111.0%
- Net Margin
- 10.8%
- ROE
- 15.9%
- ROIC
- -50.0%
Balance Sheet
- Debt/Equity
- 1.49
- Current Ratio
- 2.49
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.